The Latest Cardiac and Vascular News
Nashville, TN (May 11, 2022) – Vesalio is excited to announce the completion of patient enrollment for the CLEAR1 FDA IDE study utilizing the NeVa™ thrombectomy platform. This is an important milestone for Vesalio to complete for entering the U.S. neurovascular market to treat patients suffering from acute ischemic stroke (AIS). AIS […]
The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN, May 13, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx […]
— Human Acellular Vessels™ (HAVs™) shipped to six hospitals in Ukraine for treatment of civilian and military vascular trauma injuries — — Strengthened leadership team with appointment of Shamik Parikh M.D., as Chief Medical Officer — — Multiple scientific meeting presentations and publications highlighting clinical and preclinical HAV data — — Conference […]
Conference call scheduled for 8:30 a.m. ET today MIAMI, May 13, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the first quarter […]
CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at […]
VANCOUVER and MINNEAPOLIS, MN, May 12, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the quarter ended March 31, 2022. Recent Highlights · Achieved Q1 revenue of approximately $611,000, an increase of 35% over the same period in 2021, […]
BUILDING A SOLID BASE OF VAZALORE® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021 GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.66) […]
Company to host conference call today at 4:30 p.m. ET BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. “Our successful first quarter has kickstarted another exciting year for SomaLogic as we […]
Company Remains on Track for FDA Submission of Emergency Department (ED) Myocardial Infarction (MI) Software Product in Q2 2022 & Telehealth Solution in Q4 2022 Management to Host Webcast and Conference Call Today At 4:30 p.m. ET SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company […]
REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO “Our first quarter progress was highlighted by REN-001’s continued advancement towards the clinic and by the […]
